JOHNSON MARK E.,SEGAL ROBERT,HOFMANN THOMAS,CAPETOLA ROBERT J.
申请号：
NZ59746807
公开号：
NZ597468A
申请日:
2007.09.19
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
NZ 597468 Disclosed is the use of a pulmonary surfactant comprising one or more phospholipids and a polypeptide, in which the polypeptide, when admixed with a phospholipid, forms a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone and at least one osmotically active agent in the manufacture of a medicament for promoting mucus clearance in a patient with a pulmonary condition characterised by excessive mucus secretion or impaired mucus clearance, wherein the pulmonary condition is cystic fibrosis, bronchiectasis, primary or secondary ciliary diskinesia, COPD, or sinusitis and, wherein the synthetic pulmonary surfactant is formulated to provide the patient with a lung dose of between about 20 and 200mg total phospholipid equivalent per day and wherein the synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with an SP-B polypeptide or fragment thereof, or a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula: (ZaUb)cZd, wherein: Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K U is a hydrophobic amino acid residue independently selected from the group consisting of L and C a is 1 or 2 b has an average value of about 3 to about 8 c is 1 to 10 and d is 0 to 2.
